Immunomodulatory Peptide IDR-1018 Decreases Implant Infection and Preserves Osseointegration

Clinical Orthopaedics and Related Research

Volumn 473, Issue 9, 2015, Pages 2898-2907

  Choe, Hyonmin ^a   Narayanan, Arvind S ^a   Gandhi, Deep A ^a   Weinberg, Aaron ^b   Marcus, Randall E ^a   Lee, Zhenghong ^a   Bonomo, Robert A ^a,c   Greenfield, Edward M ^a  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b CASE WESTERN RESERVE UNIVERSITY   (United States)

^c LOUIS STOKES CLEVELAND VA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; BONE DENSITY CONSERVATION AGENT; CHEMOKINE; CYTOKINE; IDR 1018; IMMUNOMODULATING AGENT; INTERLEUKIN 1BETA; INTERLEUKIN 6; ION; MONOCYTE CHEMOTACTIC PROTEIN 1; SYNTHETIC PEPTIDE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; ANTIINFECTIVE AGENT; ANTIMICROBIAL CATIONIC PEPTIDE; AUTACOID; CCL2 PROTEIN, MOUSE; IMMUNOLOGIC FACTOR; INNATE DEFENSE REGULATING PEPTIDE 1018;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERIAL LOAD; BONE REGENERATION; BROTH DILUTION; CHRONOTHERAPY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DEVICE INFECTION; DOSE RESPONSE; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; IMMUNOMODULATION; IMPLANT INFECTION; IN VITRO STUDY; IN VIVO STUDY; INFECTION PREVENTION; MACROPHAGE ACTIVATION; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NONHUMAN; ORTHOPEDIC IMPLANT; PRIORITY JOURNAL; SINGLE DRUG DOSE; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION; TREATMENT RESPONSE; ANIMAL; C57BL MOUSE; CELL LINE; DISEASE MODEL; DRUG EFFECTS; GROWTH, DEVELOPMENT AND AGING; IMMUNOLOGY; MACROPHAGE; METABOLISM; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; PROSTHESIS-RELATED INFECTIONS; STAPHYLOCOCCAL INFECTIONS; TIME FACTOR;

ANIMALS; ANTI-BACTERIAL AGENTS; ANTIMICROBIAL CATIONIC PEPTIDES; CELL LINE; CHEMOKINE CCL2; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; IMMUNOLOGIC FACTORS; INFLAMMATION MEDIATORS; MACROPHAGES; MICE, INBRED C57BL; MICROBIAL SENSITIVITY TESTS; OSSEOINTEGRATION; PROSTHESIS-RELATED INFECTIONS; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; TIME FACTORS;

EID: 84938557654     PISSN: 0009921X     EISSN: 15281132     Source Type: Journal    
DOI: 10.1007/s11999-015-4301-2     Document Type: Article

References (45)

1. Achtman AH, Pilat S, Law CW, Lynn DJ, Janot L, Mayer ML, Ma S, Kindrachuk J, Finlay BB, Brinkman FS, Smyth GK, Hancock RE, Schofield L. Effective adjunctive therapy by an innate defense regulatory peptide in a preclinical model of severe malaria. Sci Transl Med. 2012;4:135ra164.
2. Assuma R, Oates T, Cochran D, Amar S, Graves DT. IL-1 and TNF antagonists inhibit the inflammatory response and bone loss in experimental periodontitis. J Immunol. 1998;160:403–409.
3. Bernthal NM, Stavrakis AI, Billi F, Cho JS, Kremen TJ, Simon SI, Cheung AL, Finerman GA, Lieberman JR, Adams JS, Miller LS. A mouse model of post-arthroplasty Staphylococcus aureus joint infection to evaluate in vivo the efficacy of antimicrobial implant coatings. PLoS One. 2010;5:e12580.
4. Bonsignore LA, Anderson JR, Lee Z, Goldberg VM, Greenfield EM. Adherent lipopolysaccharide inhibits the osseointegration of orthopedic implants by impairing osteoblast differentiation. Bone. 2013;52:93–101.
5. Bonsignore LA, Colbrunn RW, Tatro JM, Messerschmitt PJ, Hernandez CJ, Goldberg VM, Stewart MC, Greenfield EM. Surface contaminants inhibit osseointegration in a novel murine model. Bone. 2011;49:923–930.
6. Bowdish DM, Davidson DJ, Hancock RE. A re-evaluation of the role of host defence peptides in mammalian immunity. Curr Protein Pept Sci. 2005;6:35–51.
7. Bradley JR. TNF-mediated inflammatory disease. J Pathol. 2008;214:149–160.
8. Burnett SH, Kershen EJ, Zhang J, Zeng L, Straley SC, Kaplan AM, Cohen DA. Conditional macrophage ablation in transgenic mice expressing a Fas-based suicide gene. J Leukoc Biol. 2004;75:612–623.
9. Calhoun JH, Murray CK, Manring MM. Multidrug-resistant organisms in military wounds from Iraq and Afghanistan. Clin Orthop Relat Res. 2008;466:1356–1362.
10. Chinnery HR, Carlson EC, Sun Y, Lin M, Burnett SH, Perez VL, McMenamin PG, Pearlman E. Bone marrow chimeras and c-fms conditional ablation (Mafia) mice reveal an essential role for resident myeloid cells in lipopolysaccharide/TLR4-induced corneal inflammation. J Immunol. 2009;182:2738–2744.
11. Clinical and Laboratory Standards Institute. Methods for Dilution AntimicrobialSusceptibility Tests for Bacteria That Grow Aerobically; Approved Standard. 8th ed. Wayne, PA, USA: Clinical and Laboratory Standards Institute; 2009.
12. Dai JC, He P, Chen X, Greenfield EM. TNFalpha and PTH utilize distinct mechanisms to induce IL-6 and RANKL expression with markedly different kinetics. Bone. 2006;38:509–520.
13. Darouiche RO. Treatment of infections associated with surgical implants. N Engl J Med. 2004;350:1422–1429.
14. Diamond G, Beckloff N, Weinberg A, Kisich KO. The roles of antimicrobial peptides in innate host defense. Curr Pharm Des. 2009;15:2377–2392.
15. Finlay BB, Hancock RE. Can innate immunity be enhanced to treat microbial infections? Nat Rev Microbiol. 2004;2:497–504.
16. Franchi L, Munoz-Planillo R, Nunez G. Sensing and reacting to microbes through the inflammasomes. Nat Immunol. 2012;13:325–332.
17. Greenfield E. Particulate matter and host reactions. In: Wnek G, Bowlin G, eds. Encyclopedia of Biomaterials and Biomedical Engineering. New York, NY, USA: Taylor Francis; 2006:1–8.
18. Gristina AG, Costerton JW. Bacterial adherence to biomaterials and tissue. The significance of its role in clinical sepsis. J Bone Joint Surg Am. 1985;67:264–273.
19. Hancock RE, Sahl HG. Antimicrobial and host-defense peptides as new anti-infective therapeutic strategies. Nat Biotechnol. 2006;24:1551–1557.
20. Horibe K, Nakamichi Y, Uehara S, Nakamura M, Koide M, Kobayashi Y, Takahashi N, Udagawa N. Roles of cathelicidin-related antimicrobial peptide in murine osteoclastogenesis. Immunology. 2013;140:344–351.
21. Horowitz M, Lorenzo J. Local regulators of bone: IL-1, TNF, lymphotoxin, interferon-γ, the LIF/IL-6 family and additional cytokines. In: Bilezikian JP, Raisz LG, Martin TJ, eds. Principles of Bone Biology. 3rd ed. Amsterdam, The Netherlands: Academic Press; 2008:1209–1234.
22. Ingham E, Fisher J. The role of macrophages in osteolysis of total joint replacement. Biomaterials. 2005;26:1271–1286.
23. Johnson EN, Burns TC, Hayda RA, Hospenthal DR, Murray CK. Infectious complications of open type III tibial fractures among combat casualties. Clin Infect Dis. 2007;45:409–415.
24. Kim BN, Kim ES, Oh MD. Oral antibiotic treatment of staphylococcal bone and joint infections in adults. J Antimicrob Chemother. 2014;69:309–322.
25. Mansour SC, de la Fuente-Nunez C, Hancock RE. Peptide IDR-1018: modulating the immune system and targeting bacterial biofilms to treat antibiotic-resistant bacterial infections. J Pept Sci. 2014 Oct 31 [Epub ahead of print].
26. Mayer ML, Blohmke CJ, Falsafi R, Fjell CD, Madera L, Turvey SE, Hancock RE. Rescue of dysfunctional autophagy attenuates hyperinflammatory responses from cystic fibrosis cells. J Immunol. 2013;190:1227–1238.
27. Montanaro L, Testoni F, Poggi A, Visai L, Speziale P, Arciola CR. Emerging pathogenetic mechanisms of the implant-related osteomyelitis by Staphylococcus aureus. Int J Artif Organs. 2011;34:781–788.
28. Mookherjee N, Brown KL, Bowdish DM, Doria S, Falsafi R, Hokamp K, Roche FM, Mu R, Doho GH, Pistolic J, Powers JP, Bryan J, Brinkman FS, Hancock RE. Modulation of the TLR-mediated inflammatory response by the endogenous human host defense peptide LL-37. J Immunol. 2006;176:2455–2464.
29. Murray CK, Yun HC, Griffith ME, Thompson B, Crouch HK, Monson LS, Aldous WK, Mende K, Hospenthal DR. Recovery of multidrug-resistant bacteria from combat personnel evacuated from Iraq and Afghanistan at a single military treatment facility. Mil Med. 2009;174:598–604.
30. Niyonsaba F, Madera L, Afacan N, Okumura K, Ogawa H, Hancock RE. The innate defense regulator peptides IDR-HH2, IDR-1002, and IDR-1018 modulate human neutrophil functions. J Leukoc Biol. 2013;94:159–170.
31. Patel A, Calfee RP, Plante M, Fischer SA, Arcand N, Born C. Methicillin-resistant Staphylococcus aureus in orthopaedic surgery. J Bone Joint Surg Br. 2008;90:1401–1406.
32. Pena OM, Afacan N, Pistolic J, Chen C, Madera L, Falsafi R, Fjell CD, Hancock RE. Synthetic cationic peptide IDR-1018 modulates human macrophage differentiation. PLoS One. 2013;8:e52449.
33. Perez F, Hujer AM, Hujer KM, Decker BK, Rather PN, Bonomo RA. Global challenge of multidrug-resistant Acinetobacter baumannii. Antimicrob Agents Chemother. 2007;51:3471–3484.
34. Pribaz JR, Bernthal NM, Billi F, Cho JS, Ramos RI, Guo Y, Cheung AL, Francis KP, Miller LS. Mouse model of chronic post-arthroplasty infection: noninvasive in vivo bioluminescence imaging to monitor bacterial burden for long-term study. J Orthop Res. 2011;30:335–340.
35. Reffuveille F, de la Fuente-Nunez C, Mansour S, Hancock RE. A broad-spectrum antibiofilm peptide enhances antibiotic action against bacterial biofilms. Antimicrob Agents Chemother. 2014;58:5363–5371.
36. Rincon M. Interleukin-6: from an inflammatory marker to a target for inflammatory diseases. Trends Immunol. 2012;33:571–577.
37. Rivas-Santiago B, Castaneda-Delgado JE, Rivas Santiago CE, Waldbrook M, Gonzalez-Curiel I, Leon-Contreras JC, Enciso-Moreno JA, del Villar V, Mendez-Ramos J, Hancock RE, Hernandez-Pando R. Ability of innate defence regulator peptides IDR-1002, IDR-HH2 and IDR-1018 to protect against Mycobacterium tuberculosis infections in animal models. PLoS One. 2013;8:e59119.
38. Scott MG, Dullaghan E, Mookherjee N, Glavas N, Waldbrook M, Thompson A, Wang A, Lee K, Doria S, Hamill P, Yu JJ, Li Y, Donini O, Guarna MM, Finlay BB, North JR, Hancock RE. An anti-infective peptide that selectively modulates the innate immune response. Nat Biotechnol. 2007;25:465–472.
39. Steinstraesser L, Hirsch T, Schulte M, Kueckelhaus M, Jacobsen F, Mersch EA, Stricker I, Afacan N, Jenssen H, Hancock RE, Kindrachuk J. Innate defense regulator peptide 1018 in wound healing and wound infection. PLoS One. 2012;7:e39373.
40. Supanchart C, Thawanaphong S, Makeudom A, Bolscher JG, Nazmi K, Kornak U, Krisanaprakornkit S. The antimicrobial peptide, LL-37, inhibits in vitro osteoclastogenesis. J Dent Res. 2012;91:1071–1077.
41. Talbot GH, Bradley J, Edwards JE Jr, Gilbert D, Scheld M, Bartlett JG. Bad bugs need drugs: an update on the development pipeline from the Antimicrobial Availability Task Force of the Infectious Diseases Society of America. Clin Infect Dis. 2006;42:657–668.
42. Wieczorek M, Jenssen H, Kindrachuk J, Scott WR, Elliott M, Hilpert K, Cheng JT, Hancock RE, Straus SK. Structural studies of a peptide with immune modulating and direct antimicrobial activity. Chem Biol. 2010;17:970–980.
43. Wiegand I, Hilpert K, Hancock RE. Agar and broth dilution methods to determine the minimal inhibitory concentration (MIC) of antimicrobial substances. Nat Protoc. 2008;3:163–175.
44. Yadav A, Saini V, Arora S. MCP-1: chemoattractant with a role beyond immunity: a review. Clin Chim Acta. 2010;411:1570–1579.
45. Yun HC, Branstetter JG, Murray CK. Osteomyelitis in military personnel wounded in Iraq and Afghanistan. J Trauma. 2008;64(Suppl):S163–168; discussion S168.